DE60324387D1 - Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie - Google Patents

Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie

Info

Publication number: DE60324387D1
Authority: DE; Germany
Prior art keywords: amylin; amylinanaloga; hypertriglyceridemia; dyslipidemia; treatment
Prior art date: 2002-01-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60324387T

Other languages

English (en)

Inventor

Orville G Kolterman

Christian Weyer

David G Maggs

Mark Fineman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amylin Pharmaceuticals LLC

Original Assignee

Amylin Pharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-08

Filing date

2003-01-08

Publication date

2008-12-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23362445&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60324387(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-01-08 Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC

2008-12-11 Application granted granted Critical

2008-12-11 Publication of DE60324387D1 publication Critical patent/DE60324387D1/de

2023-01-09 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

DE60324387T 2002-01-08 2003-01-08 Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie Expired - Lifetime DE60324387D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34712802P	2002-01-08	2002-01-08
PCT/US2003/000369 WO2003057244A2 (en)	2002-01-08	2003-01-08	Use of amylin agonists to modulate triglycerides

Publications (1)

Publication Number	Publication Date
DE60324387D1 true DE60324387D1 (de)	2008-12-11

Family

ID=23362445

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60324387T Expired - Lifetime DE60324387D1 (de)	2002-01-08	2003-01-08	Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie

Country Status (9)

Country	Link
US (1)	US20030130177A1 (de)
EP (1)	EP1474164B1 (de)
AT (1)	ATE412421T1 (de)
AU (1)	AU2003235742B2 (de)
CA (1)	CA2475173A1 (de)
DE (1)	DE60324387D1 (de)
ES (1)	ES2316757T3 (de)
NZ (1)	NZ534557A (de)
WO (1)	WO2003057244A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2316757T3 (es) *	2002-01-08	2009-04-16	Amylin Pharmaceuticals, Inc.	Uso de agonistas de amilina para modular trigliceridos.
JP5114381B2 (ja)	2005-03-31	2013-01-09	アミリン・ファーマシューティカルズ，インコーポレイテッド	精神疾患および障害治療用アミリンおよびアミリンアゴニスト
EP1912666A2 (de) *	2005-07-22	2008-04-23	Amylin Pharmaceuticals, Inc.	Verwendung von amylin und amylin-agonisten als kardioprotektive oder myoprotektive mittel
JP5252435B2 (ja) *	2006-03-15	2013-07-31	ノボ・ノルデイスク・エー／エス	アミリン誘導体
EP2036923A1 (de) *	2007-09-11	2009-03-18	Novo Nordisk A/S	Verbesserte Derivate von Amylin
JP5703226B2 (ja) *	2008-10-21	2015-04-15	ノヴォノルディスクアー／エス	アミリン誘導体
AU2010317842A1 (en)	2009-11-16	2012-07-12	Mellitech	[1,5]-diazocin derivatives
BR102013017626A2 (pt) *	2013-06-14	2015-02-10	Univ Rio De Janeiro	Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8720115D0 (en) *	1987-08-26	1987-09-30	Cooper G J S	Treatment of diabetes mellitus
US5367052A (en) *	1987-04-27	1994-11-22	Amylin Pharmaceuticals, Inc.	Amylin peptides
HU222249B1 (hu) *	1991-03-08	2003-05-28	Amylin Pharmaceuticals Inc.	Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
CA2115159A1 (en) *	1991-08-08	1993-02-09	Jeffrey A. Bibbs	Production of peptide amides
US6143718A (en) *	1995-06-07	2000-11-07	Amylin Pharmaceuticals, Inc.	Treatment of Type II diabetes mellutis with amylin agonists
ES2247676T3 (es) *	1997-01-07	2006-03-01	Amylin Pharmaceuticals, Inc.	Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
WO1998045313A1 (en) *	1997-04-04	1998-10-15	Amylin Pharmaceuticals, Inc.	Novel uncoupling protein and methods of use
US7910548B2 (en) *	1997-06-06	2011-03-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity
US6087334A (en) *	1998-08-21	2000-07-11	Amylin Pharmaceuticals, Inc.	Anti-diabetic peptides
CN1186017C (zh) *	2001-10-09	2005-01-26	陈立民	防治糖尿病、高脂血症和肥胖症的药物的配制方法
ES2316757T3 (es) *	2002-01-08	2009-04-16	Amylin Pharmaceuticals, Inc.	Uso de agonistas de amilina para modular trigliceridos.

2003
- 2003-01-08 ES ES03729360T patent/ES2316757T3/es not_active Expired - Lifetime
- 2003-01-08 AT AT03729360T patent/ATE412421T1/de not_active IP Right Cessation
- 2003-01-08 AU AU2003235742A patent/AU2003235742B2/en not_active Ceased
- 2003-01-08 DE DE60324387T patent/DE60324387D1/de not_active Expired - Lifetime
- 2003-01-08 US US10/337,979 patent/US20030130177A1/en not_active Abandoned
- 2003-01-08 EP EP03729360A patent/EP1474164B1/de not_active Revoked
- 2003-01-08 WO PCT/US2003/000369 patent/WO2003057244A2/en not_active Application Discontinuation
- 2003-01-08 NZ NZ534557A patent/NZ534557A/en not_active IP Right Cessation
- 2003-01-08 CA CA002475173A patent/CA2475173A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2003235742A1 (en)	2003-07-24
US20030130177A1 (en)	2003-07-10
AU2003235742B2 (en)	2008-08-07
WO2003057244A2 (en)	2003-07-17
NZ534557A (en)	2007-10-26
EP1474164B1 (de)	2008-10-29
CA2475173A1 (en)	2003-07-17
ATE412421T1 (de)	2008-11-15
EP1474164A2 (de)	2004-11-10
WO2003057244A3 (en)	2003-12-18
ES2316757T3 (es)	2009-04-16

Similar Documents

Publication	Publication Date	Title
ATE365165T1 (de)	2007-07-15	Diaminopyrimidine und deren verwendung als angiogenesehemmer
CY1115361T1 (el)	2017-01-04	Στερεες μορφες περιλαμβανοντας (+)-2-[1-(3-αιθοξυ-4-μεθοξυφαινυλ)-2-μεθυλσουλφονυλαιθυλ]-4-ακετυλαμινοϊσοϊνδολιν-1,3-διονη, συνθεσεις εξ' αυτων, και χρησεις εξ' αυτων
EA200601555A1 (ru)	2007-02-27	Замещенные индазол-о-глюкозиды
DE602004017736D1 (de)	2008-12-24	Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE69737592D1 (de)	2007-05-24	Mittel gegen juckreiz
NO20034056D0 (no)	2003-09-12	Proliferative sykdommer
DE60105547D1 (de)	2004-10-21	Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
YU21401A (sh)	2004-03-12	Tetrahidropiridoetri
ATE553086T1 (de)	2012-04-15	Substituierte heterocyclische verbindungen und deren verwendung zur behandlung der multipler medikamentenresistenz
NO20052760D0 (no)	2005-06-07	Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
DE60033030D1 (de)	2007-03-08	Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
DE602005005810D1 (de)	2008-05-15	Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE279181T1 (de)	2004-10-15	Verwendung von 5ht-6 antagonisten zur behandlung adhd
AR038563A1 (es)	2005-01-19	Composicion de ziprasidona y controles sinteticos
ATE420097T1 (de)	2009-01-15	Substituierte sapogenine und ihre verwendung
BR0202519B1 (pt)	2012-09-18	métodos para tratamento de material de madeira e para tratamento microbicida de material de madeira.
ATE336996T1 (de)	2006-09-15	Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem
DE60008143D1 (de)	2004-03-11	Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE480265T1 (de)	2010-09-15	Verwendung von zahnfleischfibroblasten zur behandlung von vaskulären zellen
DE60324387D1 (de)	2008-12-11	Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie
DE602004022035D1 (de)	2009-08-27	Verwendung von pthalide derivativen zur behandlung
CY1110043T1 (el)	2015-01-14	2-αμινοβενζουλ παραγωγα
ATE410235T1 (de)	2008-10-15	Behandlung von ballastwasser
DE69827387D1 (de)	2004-12-09	Verwendung von pramipexol zur behandlung von restless-legs-syndrom
DE60213365D1 (de)	2006-09-07	Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen

Legal Events

Date	Code	Title	Description
2009-10-08	8363	Opposition against the patent
2010-05-12	8328	Change in the person/name/address of the agent	Representative=s name: HOFFMANN & EITLE, 81925 MUENCHEN